|Guidelines for good clinical practice (GCP) for trials on pharmaceutical products (WHO Technical Report Series, No. 850, 1995, Annex 3) (WHO, 1995, 36 p.)|
|5. RESPONSIBILITIES OF THE SPONSOR|
If the sponsor elects or is required to terminate the clinical trial prematurely, then the investigator(s), ethics committee and relevant authorities must be notified of this decision, and of the reasons for termination.